Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Investing Activities (2020 - 2024)

Immuneering (IMRX) has 5 years of Cash from Investing Activities data on record, last reported at $5.5 million in Q4 2024.

  • For Q4 2024, Cash from Investing Activities rose 75.26% year-over-year to $5.5 million; the TTM value through Dec 2024 reached $26.4 million, up 262.3%, while the annual FY2024 figure was $26.4 million, 262.3% up from the prior year.
  • Cash from Investing Activities reached $5.5 million in Q4 2024 per IMRX's latest filing, up from -$5.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $22.2 million in Q2 2022 and bottomed at -$52.8 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$5398.8, with a median of $1.6 million recorded in 2020.
  • Peak YoY movement for Cash from Investing Activities: plummeted 941746.24% in 2021, then surged 111852.97% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$38058.0 in 2020, then tumbled by 59829.41% to -$22.8 million in 2021, then soared by 135.74% to $8.2 million in 2022, then plummeted by 61.57% to $3.1 million in 2023, then skyrocketed by 75.26% to $5.5 million in 2024.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $5.5 million in Q4 2024, -$5.4 million in Q3 2024, and $5.0 million in Q2 2024.